Sanofi Q1 Earnings Call Highlights [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
income up 10.9% and business EPS up 14%, and it reaffirmed 2026 guidance for high single-digit sales growth at constant exchange rates. Dupixent remains the growth engine, delivering about €4.2 billion in Q1 across nine approved indications and ~1.4 million patients, and Sanofi outlined a “defend, extend and innovate” plan — including patents through 2031–2045 and higher-dose/co-formulation strategies — to sustain its franchise. The launch portfolio contributed 14% of Q1 sales and grew 44% year-over-year (22% ex-acquisitions) with key products like ALTUVIIIO (€325m), Beyfortus (€284m), Sarclisa (€167m) and Ayvakit (€170m) , while pipeline updates (label expansions, Rezurock, Tzield, lunsekimig, amlitelimab) and business-development plans remain priorities amid an expected negative BOI impact from the Regeneron R&D reimbursement step-down (roughly ~€400m in 2026 and ~€700m in 2027). Interested in Sanofi? Here are five stocks we like better. Analysts Can't Get Enough of These Li
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapsesGlobeNewswire
- Sanofi SA (SNY) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Developments [Yahoo! Finance]Yahoo! Finance
- ???????????(ATV)?????????????????(UTV)??:???????????? [CNET News]CNET News
- BNP Paribas Downgrades Sanofi (SNY) with ‘Unlikely Near-Term Rerating' [Yahoo! Finance]Yahoo! Finance
- How The Sanofi (ENXTPA:SAN) Narrative Is Shifting After Valuation Reset And Pipeline Updates [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 4/23/26 - Form 6-K
- 4/15/26 - Form 6-K
- 4/10/26 - Form SCHEDULE
- SNY's page on the SEC website